MTF Biologics Debuts CartiMax Viable Cartilage Allograft

MTF Biologics and ConMed launched CartiMax® Viable Cartilage Allograft, a putty-like cartilage designed to fill lesions in the knee, foot and ankle.

CartiMax demonstrates stable viability up to one year post-cryopreservation, allowing surgeons to schedule procedures without a waiting list. Surgeons can mold and fill up to a 5cm² lesion without the use of templates or anchors. It requires minimal preparation, which yields time savings in the O.R. and its viable chondrocytes and extracellular matrix contain the building blocks for cartilage repair, such as type II collagen, proteoglycans and endogenous growth factors.

Source: MTF Biologics